|
Total
|
327
|
100
|
48
|
100
|
205
|
100
| |
|
Accreditation level
| | | | | | | |
|
Medical Center
|
18
|
5
|
0
|
0
|
1
|
0
| |
|
Regional Hospital
|
68
|
21
|
2
|
4
|
8
|
4
| |
|
District Hospital
|
241
|
74
|
46
|
96
|
196
|
96
|
0.00004
|
|
Ownership
| | | | | | | |
|
Public Hospital
|
67
|
20
|
7
|
15
|
17
|
8
| |
|
Non-profit Hospital
|
65
|
20
|
3
|
6
|
4
|
2
| |
|
Private Hospital
|
195
|
60
|
38
|
79
|
184
|
90
|
0.00004
|
|
BNHI Regions
| | | | | | | |
|
Taipei
|
78
|
24
|
12
|
25
|
26
|
13
| |
|
Northern
|
49
|
15
|
6
|
12
|
23
|
11
| |
|
Central
|
81
|
25
|
5
|
10
|
40
|
20
| |
|
Southern
|
49
|
15
|
9
|
19
|
40
|
20
| |
|
Kao-Ping
|
59
|
18
|
14
|
29
|
72
|
35
| |
|
Eastern
|
11
|
3
|
2
|
5
|
4
|
1
|
0.00034
|
| |
mean
|
Std
|
mean
|
Std
|
mean
|
Std
| |
|
Herfindahl-Hirschman Indexes1 (HHI)
|
0.339
|
0.137
|
0.45
|
0.180
|
0.57
|
0.223
|
0.00005
|
|
Number of doctors who prescribed TZD drug
|
34.02
|
66.97
|
4.86
|
5.16
|
-
|
-
| |
|
Initial TZD use after TA (month)
|
15.19
|
11.61
|
36.79
|
16.00
|
-
|
-
| |
|
Total DDD of DM2 (DDD)
|
37917.47
|
77383.05
|
8468
|
12601
|
2243
|
3958
|
0.00005
|
| |
mean
|
Std
| | | | | |
|
Maximum monthly TZD penetration3
|
0.117
|
0.067
|
-
|
-
|
-
|
-
| |
|
Time between initial adoption and the maximum penetration (month)
|
26.14
|
13.16
|
-
|
-
|
-
|
-
| |
| |
mean
|
Std
| | | | | |
|
Peak use (maximum monthly prescription of TZD in DDD)
|
6970.01
|
12678.72
|
-
|
-
|
-
|
-
| |
|
The time between initial adoption to the maximum prescription of TZD (month)
|
27.02
|
13.17
|
-
|
-
|
-
|
-
| |
|
Prescription Speed (monthly growth on TZD prescription in DDD)
|
252.65
|
374.31
|
-
|
-
|
-
|
-
| |
|
Maximum prescription in DDD
| | | | | | | |
|
25% quantile
| |
924.83
|
-
|
-
|
-
|
-
| |
|
50% quantile
| |
2488
|
-
|
-
|
-
|
-
| |
|
75% quantile
| |
6454.83
|
-
|
-
|
-
|
-
| |
|
Rate of penetration
| | | | | | | |
|
25% quantile
| |
39.99
|
-
|
-
|
-
|
-
| |
|
50% quantile
| |
111.22
|
-
|
-
|
-
|
-
| |
|
75% quantile
| |
293.97
|
-
|
-
|
-
|
-
| |
